Psoriasis

Psoriasis | Access and Reimbursement | US | 2019

MARKET OUTLOOK

In the past decade, tumor necrosis factor-alpha (TNF-α) inhibitors, including AbbVie’s Humira and Amgen’s Enbrel, and Janssen’s interleukin IL-12/23 inhibitor Stelara have…

Psoriasis | Unmet Need | US/EU | 2019

With a drug-treated population of more than 4 million people in the United States and EU5, the psoriasis market has been a lucrative space for drug developers, resulting in a plethora of approved…

Psoriasis – Epidemiology – Mature Markets

DRG Epidemiology's coverage of psoriasis (PsO) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the total symptomatic prevalence of PsO…

Psoriasis – Epidemiology – Emerging Markets

DRG Epidemiology's coverage of psoriasis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of PsO for each country, as well…

Psoriasis – Epidemiology – Asia Pacific

DRG Epidemiology's coverage of psoriasis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of PsO for each country, as well…